GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received clearance from the U.S Food and Drug Administration(FDA) for its Investigational New Drug (IND) application for GEN6050X, a first-in-class base editing drug for Duchenne Muscular Dystrophy (DMD). GenAssist is planning to conduct clinical study globally for GEN6050X.

GenAssist Announces FDA Approval of New Drug Application for GEN6050X Exon 50 Skipping Therapy

👉 Read More: dmdwarrior.com

#dmd #duchenne #GenAssist #GEN6050X #exon50 #exon50skipping